Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2017 AND APRIL 2018. Refer to TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma and TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | brentuximab vedotin (Adcetris®) | ||
| Formulation | 50 mg powder for concentrate for solution for infusion | ||
| Reference number | 1255 | ||
| Indication | Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option; as well as for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) |
||
| Company | Takeda UK Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 1215 | ||
| NMG meeting date | 15/04/2015 | ||
| AWMSG meeting date | 20/05/2015 | ||
| Ratification by Welsh Government | 26/06/2015 | ||
| Date of issue | 30/06/2015 | ||
| NICE guidance | TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma and TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
||
| Commercial arrangement | PAS | ||